Corona Remedies IPO Day 2: Check GMP, Subscription Status & Key Highlights
The Corona Remedies IPO enters its second day of subscription today, 9 December 2025. By the end of the first day, the issue was subscribed to 0.62 times overall. The bidding window is scheduled to close on December 10, 2025.
Corona Remedies IPO: Issue Details
Issue Size: The Corona Remedies IPO is a book-building issue of ?655.37 crore, consisting entirely of an offer for sale (OFS) of 0.62 crore shares.?
Price Band: The price band is set between ?1008 and ?1062 per share.
Lot Size & Minimum Investment: The lot size for an application is 14, and the minimum investment required is ?14,868 (for retail investors).?
Book-running lead managers: JM Financial Limited, IIFL Capital Services Limited, Kotak Mahindra Capital Company Limited?
Registrar: Bigshare Services Private Limited
Allotment Date: The basis of allotment will be finalised by December 11, 2025.?
Listing Date: The tentative listing date on NSE and BSE is December 15, 2025.?
Corona Remedies IPO Day 2 Subscription Status
[4-December-2025 17:00:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
1.67 |
|
Non-Institutional Investors |
26.80 |
|
Retail Individual Investors (RIIs) |
6.37 |
|
Employees |
4.35 |
|
Total |
9.33 |
Corona Remedies IPO Day 1 Subscription Status
[8-December-2025 17:00:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.00 |
|
Non-Institutional Investors |
0.79 |
|
Retail Individual Investors (RIIs) |
0.87 |
|
Employees |
0.44 |
|
Total |
0.62 |
Utilisation of IPO Proceeds
As the issue is entirely an offer for sale, the company will not receive any proceeds, and they will be allocated directly to selling shareholders.?
Corona Remedies IPO GMP
As per media reports, the Grey Market Premium (GMP) of Corona Remedies is reported at ?262. Considering the upper price band of ?1062, the shares are expected to list at ?1324 apiece, i.e., a 24.67% premium.?
Corona Remedies Business Overview
Corona Remedies is a pharmaceutical company engaged in the development, manufacturing, and marketing of branded formulations across key therapeutic categories, including women’s health, cardio-diabetes, pain and musculoskeletal care, urology, and a range of multispecialty segments.?
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.